ARCHIVES

DCPC Advisors Upset At NCAB Over Why Decision, But Move On

This article is from The Cancer Letter archive.

Vol. 17 No. 06 | February 8, 1991

Download PDF Visit The Full Archive

Related Articles

Auditor Raymond Weiss Finds “Incredible” Protocol Violations–26% Of Patients Were Ineligible For C225 Study

June 21, 2002

FDA News: Zydelig approved in three B-cell blood cancers

August 1, 2014

Intense Therapies Better Than Lower Dose For AML

November 26, 2004

PCORI Approves $54.8 Million For Clinical Effectiveness Research

August 1, 2014

NCI Advisory Group Meetings for July

June 27, 1975

Prevention Clinical Trials Heads Greenwalk Priority Lists For ‘86

February 8, 1985